Ghent University Academic Bibliography

Your filters: cql: author="Yu, Brian" or (type any "bookEditor issueEditor" and editor="Yu, Brian")

Add to list
- Journal Article
- A1
- open access
Safety and efficacy of tarlatamab in patients with neuroendocrine prostate cancer : results from the Phase 1b DeLLpro-300 study

Rahul Aggarwal, Sylvie Rottey (UGent) , Alice Bernard-Tessier, Begoña Mellado, Takeo Kosaka, Walter M Stadler, Lisa Horvath, Richard Greil, Bert O'Neil, Bilal A Siddiqui, et al.

(2025) CLINICAL CANCER RESEARCH. 31(18). p.3854-3863
Add to list
Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC)

Rahul Raj Aggarwal, Sylvie Rottey (UGent) , Alice Bernard-Tessier, Begona Mellado-Gonzalez, Takeo Kosaka, Walter Michael Stadler, Shahneen Sandhu, Brian Yu, Crystal Shaw, Chia-Hsin Ju, et al.

(2024) JOURNAL OF CLINICAL ONCOLOGY. In Journal of Clinical Oncology 42(16, Supplement S).
Add to list
Pharmacokinetics and pharmacodynamics of ceftolozane/tazobactam in critically ill patients with augmented renal clearance

David P. Nicolau, Jan De Waele (UGent) , Joseph L. Kuti, Luzelena Caro, Kajal B. Larson, Brian Yu, Elaine Gadzicki, Zhen Zeng, Elizabeth G. Rhee and Matthew L. Rizk

(2021) INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. 57(4).
Add to list
Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia

Luzelena Caro, David P Nicolau, Jan De Waele (UGent) , Joseph L Kuti, Kajal B Larson, Elaine Gadzicki, Brian Yu, Zhen Zeng, Adedayo Adedoyin and Elizabeth G Rhee

(2020) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 75(6). p.1546-1553

Academic Bibliography

Safety and efficacy of tarlatamab in patients with neuroendocrine prostate cancer : results from the Phase 1b DeLLpro-300 study

Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC)

Pharmacokinetics and pharmacodynamics of ceftolozane/tazobactam in critically ill patients with augmented renal clearance

Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia

Contents

Support

Contact